Document Detail

The impact of topiramate (Topamax®) therapy on the development of aggressive and/or agitated behavior.
MedLine Citation:
PMID:  21987528     Owner:  NLM     Status:  MEDLINE    
The use of topiramate therapy to control the neuropsychiatric and behavioral disturbances in individuals with mental and/or developmental disabilities with co-occurring psychiatric disturbances has become a standard of practice in many long-term care assisted living facilities. With increased utilization of this anticonvulsant, there has been a rise in the number documented cases of agitation and/or aggressive behavior associated with topiramate therapy. It is the purpose of this article to explore the current literature documenting the connection between topiramate utilization and the development of aggressive and/or agitated behavior.
Abimbola Farinde
Related Documents :
22451778 - Frontal osteomyelitis (pott's puffy tumour) associated with pasteurella multocida-a cas...
16015638 - Results of multiple-slide, blinded review of papanicolaou slides in the context of liti...
22643318 - Laryngeal paraganglioma in an irradiated neck.
15359188 - 2003 review of neutron and non-neutron nuclear data.
15334508 - Pulmonary lymphangiectasia: diagnosis and clinical course.
21918898 - Henoch-schönlein purpura with uveitis: an unusual case and review of literature.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-10-10
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  24     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-01-18     Completed Date:  2012-05-04     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  568-70     Citation Subset:  IM    
Lufkin State Supported Living Center, Nacogdoches, TX 75965, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aggression / psychology*
Anticonvulsants / adverse effects*
Epilepsy / drug therapy*
Fructose / adverse effects,  analogs & derivatives*
Mental Disorders / chemically induced*
Psychomotor Agitation / etiology*,  psychology
Reg. No./Substance:
0/Anticonvulsants; 0H73WJJ391/topiramate; 30237-26-4/Fructose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparative Effectiveness of Dalteparin and Enoxaparin in a Hospital Setting.
Next Document:  A Cost-Effectiveness Evaluation of Hospital Discharge Counseling by Pharmacists.